3 Oleochemical Additives Leader, Generics and Active Ingredients Company and Integrated Apparel Maker Stocks With a Strong Future Roadmap: Fine Organic Industries, Dr. Reddy’s Laboratories and KPR Mill
- November 4, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Fine Organic Industries, Dr. Reddy’s Laboratories and KPR Mill: ROE of 11.1% to 15.7% and FY22 to FY26 revenue CAGR of 6.8% to 12.3%. Prices as of 3 Nov 2026.
Quick Answer
The three additive, generic drug and apparel maker stocks to watch are Fine Organic Industries, Dr. Reddy’s Laboratories and KPR Mill. Their return on equity ranges from 11.1% to 15.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 12.3%. Fine Organic Industries has the highest return on equity at 15.7%, while Dr. Reddy’s Laboratories has the fastest revenue growth at 12.3% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.
Additive, generic drug and apparel maker stocks give investors a way to track businesses that sit close to everyday demand in India. Fine Organic Industries, Dr. Reddy’s Laboratories and KPR Mill cover an oleochemical additives leader, a generics company and an integrated apparel maker.
This list covers three additive, generic drug and apparel maker stocks with complete current figures: Fine Organic Industries, Dr. Reddy’s Laboratories and KPR Mill. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Additive, Generic Drug and Apparel Maker Stocks?
Additive, generic drug and apparel maker stocks are listed companies that make additives for food, plastics and cosmetics, supply generics and active ingredients in India and global markets, and spin yarn, knit fabric and stitch garments for global brands. Their earnings depend on export orders and customer industries.
Additive, Generic Drug and Apparel Maker Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Fine Organic Industries | 5,089 | 16,561 | 37.8 | 35.1 | 15.7 | 0.03 |
| Dr. Reddy’s Laboratories | 1,368.3 | 103,667 | 32.6 | 36.0 | 11.1 | 0.20 |
| KPR Mill | 1,160 | 34,974 | 38.3 | 33.8 | 15.2 | 0.10 |
On valuation, Dr. Reddy’s Laboratories trades at a P/E below the industry P/E, while Fine Organic Industries and KPR Mill trade above it, which reflects the growth the market already expects. Readers comparing additive, generic drug and apparel maker stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in additive, generic drug and apparel maker stocks can use the coming numbers to test whether growth is holding.
Why Do Additive, Generic Drug and Apparel Maker Stocks Have a Strong Roadmap in India?
Additive, generic drug and apparel maker stocks have a strong roadmap in India because growing demand for specialty additives, steady use of generics and strong export orders for garments keep widening the market for these export linked companies.
- Additives. Food and plastics makers use specialty inputs.
- Generics. Medicines reach North America, Europe and India.
- Garments. Integrated mills serve global brands.
Why Fine Organic Industries Features Among These Additive, Generic Drug and Apparel Maker Stocks
Among the additive, generic drug and apparel maker stocks on this list, Fine Organic Industries is a leading maker of oleochemical-based additives used in food, plastics, cosmetics and coatings, selling to customers in India and overseas.
The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1.
Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore.
Roadmap: The company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.
What to watch: Monitor raw material prices, export demand and the pace of new capacity addition.
Why Dr. Reddy’s Laboratories Features Among These Additive, Generic Drug and Apparel Maker Stocks
Among the specialty chemical, pharma and textile shares on this list, Dr. Reddy’s Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.
Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.
Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.
Why KPR Mill Features Among These Additive, Generic Drug and Apparel Maker Stocks
Among the three companies on this list, KPR Mill is a Coimbatore-based, vertically integrated apparel maker that spins yarn, knits fabric and stitches garments for global brands. It also runs sugar and ethanol operations and a growing retail business.
In the June 2026 quarter, revenue grew 9.3% year on year to Rs 1,970 crore, while net profit rose 21.6% to Rs 259 crore. Revenue rose from Rs 4,910 crore in FY22 to Rs 6,784 crore in FY26, a compound annual growth rate of 8.4%.
Net profit grew from Rs 815 crore in FY25 to Rs 866 crore in FY26, a rise of 6.3%. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 34,974 crore. The stock trades at a P/E of 38.3, above the industry P/E of 33.8.
Roadmap: The company is adding garment and fabric capacity and deepening ties with large international apparel buyers. Its control over each step from yarn to garment supports delivery speed and quality.
What to watch: Track garment export orders, capacity additions and the progress of the retail business.
Fine Organic Industries vs Dr. Reddy’s Laboratories vs KPR Mill on Key Financials
The table below sets the three additive, generic drug and apparel maker stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Fine Organic Industries | 1,909 | 2,482 | 6.8% | 417 | 16.8% |
| Dr. Reddy’s Laboratories | 22,030 | 35,059 | 12.3% | 4,158 | 11.9% |
| KPR Mill | 4,910 | 6,784 | 8.4% | 866 | 12.8% |
Fine Organic Industries posts the highest return on equity in this group at 15.7%. Dr. Reddy’s Laboratories combines the largest FY26 revenue at Rs 35,059 crore with the fastest revenue growth, a 12.3% compound annual rate. A useful habit with additive, generic drug and apparel maker stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Additive, Generic Drug and Apparel Maker Stocks
Every theme carries risks that deserve a check before any decision. For these additive, generic drug and apparel maker stocks, the main points are: Long-term specialty chemical, pharma and textile shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Currency moves. Export earnings move with the rupee.
- Pricing pressure. Generic prices can change by market.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter additive, generic drug and apparel maker stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Additive, Generic Drug and Apparel Maker Stocks
Additive, generic drug and apparel maker stocks work best when investors track growth, valuation and return on equity side by side. Fine Organic Industries, Dr. Reddy’s Laboratories and KPR Mill each have a clear plan to grow. Based on the 3 November 2026 close, Fine Organic Industries trades at Rs 5,089, Dr. Reddy’s Laboratories at Rs 1,368.3 and KPR Mill at Rs 1,160. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these additive, generic drug and apparel maker stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track additive, generic drug and apparel maker stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are additive, generic drug and apparel maker stocks?
Ans. Additive, generic drug and apparel maker stocks are listed companies that make additives for food, plastics and cosmetics, supply generics and active ingredients in India and global markets, and spin yarn, knit fabric and stitch garments for global brands. Their earnings depend on export orders and customer industries. This list looks at three of them, Fine Organic Industries, Dr. Reddy’s Laboratories and KPR Mill, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.
Which additive, generic drug and apparel maker stocks are covered in this list?
Ans. This list covers Fine Organic Industries, Dr. Reddy’s Laboratories and KPR Mill. Based on the 3 November 2026 close, Fine Organic Industries traded at Rs 5,089, Dr. Reddy’s Laboratories at Rs 1,368.3 and KPR Mill at Rs 1,160. Their return on equity ranges from 11.1% to 15.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 12.3%.
Why do additive, generic drug and apparel maker stocks have a strong future roadmap in India?
Ans. Additive, generic drug and apparel maker stocks have a strong roadmap in India because growing demand for specialty additives, steady use of generics and strong export orders for garments keep widening the market for these export linked companies. The main drivers are as follows. Additives. Food and plastics makers use specialty inputs. Generics. Medicines reach North America, Europe and India. Garments. Integrated mills serve global brands. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Fine Organic Industries performed financially?
Ans. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1. Looking ahead, the company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.
How has Dr. Reddy’s Laboratories performed financially?
Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
How has KPR Mill performed financially?
Ans. Revenue rose from Rs 4,910 crore in FY22 to Rs 6,784 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 815 crore in FY25 to Rs 866 crore in FY26, a rise of 6.3%. In the June 2026 quarter, revenue grew 9.3% year on year to Rs 1,970 crore, while net profit rose 21.6% to Rs 259 crore. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 34,974 crore. The stock trades at a P/E of 38.3, above the industry P/E of 33.8. Looking ahead, the company is adding garment and fabric capacity and deepening ties with large international apparel buyers. Its control over each step from yarn to garment supports delivery speed and quality.
What risks should investors check before buying additive, generic drug and apparel maker stocks?
Ans. Investors should check a few risks before buying additive, generic drug and apparel maker stocks. Currency moves. Export earnings move with the rupee. Pricing pressure. Generic prices can change by market. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of additive, generic drug and apparel maker stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
